“We envision the field of mammography moving from age-based screening protocols to ‘risk adaptive screening’.
ICAD announced the commercial availability of its ProFound AI for breast cancer detection in digital breast tomosynthesis in 2018, which delivers critical benefits, including improvements of cancer detection rates, a decrease in unnecessary patient recalls, and shorter reading times for radiologists. Understanding short-term risk will open the door to new paradigms in both the prevention and treatment of breast cancer.” Our research using the iCAD AI technology has shown that by simply using the information available in the mammogram images, we can more accurately stratify women based on short-term risk. “Most current risk models are population-based and focus on lifetime or long-term risk. “Models that accurately predict an individual woman’s risk of developing breast cancer are paramount to transitioning from age-based screening to risk-based screening,” said Per Hall, Professor, Senior Physician, Karolinska Institutet. Among other things, the model now takes asymmetry of mammographic features and masking of tumors into consideration. Since this publication, these results have been improved upon through the use of iCAD’s latest ProFound™ AI algorithm.
These data indicated that the model developed enabled early identification of women who were at a high-risk for breast cancer and it was determined that additional examinations were warranted. Promising early results based on mammography images from over 70,000 Swedish women enrolled in The Karolinska Mammography Project for Risk Prediction of Breast Cancer (Karma) study were published in Breast Cancer Research in 2017. This partnership builds on an existing research agreement whereby researchers at the Karolinska Institutet developed a breast cancer risk prediction model using information identified in mammography images provided by iCAD’s AI cancer detection and density assessment solutions. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced their intent to enter into an exclusive relationship with two leading researchers at The Karolinska Institutet in Stockholm, Sweden, one of the world’s foremost medical research universities, to develop an artificial intelligence (AI)-based solution that will identify a women’s individual risk of developing breast cancer.
0 kommentar(er)
